Lycia Therapeutics Raises $75M Series D to Advance Its LYTAC Protein Degradation Platform

Lycia Therapeutics has raised an oversubscribed $75M Series D to accelerate development of its LYTAC platform, a technology designed to eliminate disease-causing extracellular proteins by directing them to the cell's natural lysosomal degradation system. The financing was co-led by Janus Henderson Investors and Balyasny Asset Management, with participation from Adage Capital Management, HBM Healthcare Investments, OrbiMed, Eli Lilly and Company, Franklin Templeton, Invus, RTW Investments, and Venrock Healthcare Capital Partners.

The South San Francisco biotechnology company is advancing its lead therapeutic programs, LCA-0061 and LCA-0321, toward early clinical proof of concept while expanding its broader cataLYTAC and LYTAC pipeline. The financing continues a pattern of institutional support behind one of biotechnology's most closely watched extracellular protein degradation platforms and reflects a broader shift in biotech investing, where experienced investors increasingly back platform companies capable of generating multiple therapeutic opportunities rather than relying on a single experimental asset.

What Happened

Founded in 2019, Lycia Therapeutics was created by Versant Ventures through its Inception Sciences Discovery Engine in collaboration with academic founder Carolyn Bertozzi, Ph.D., whose foundational research established the scientific framework for Lysosomal Targeting Chimeras, or LYTACs. The company is headquartered in South San Francisco, California, and focuses on developing therapeutics that selectively degrade extracellular and membrane-bound disease targets.

The $75M Series D follows a consistent trajectory of financing milestones that have steadily expanded investor conviction. Lycia Therapeutics previously completed a $50M Series A, a $70M Series B, and a $106.6M Series C. In 2021, the company entered into a strategic research collaboration with Eli Lilly and Company that included a $35M upfront payment and the potential for future milestone payments tied to multiple therapeutic programs.

The latest financing supports advancement of LCA-0061 for allergic diseases, including food allergy, allergic asthma, and chronic spontaneous urticaria. It also accelerates development of LCA-0321 for Graves' disease and thyroid eye disease while supporting additional cataLYTAC and LYTAC programs targeting autoimmune and inflammatory diseases.

Execution remains as important as discovery. Under the leadership of CEO Aetna Wun Trombley, Ph.D., alongside academic founder Carolyn Bertozzi, Ph.D., and CSO Steve Staben, Ph.D., Lycia Therapeutics has evolved from a platform built on breakthrough academic research into a company advancing multiple therapeutic candidates toward clinical milestones.

Why the LYTAC Platform Matters

Drug discovery has traditionally relied on blocking biological activity. Lycia Therapeutics is pursuing a different strategy by removing disease-causing proteins altogether through a platform that binds extracellular or membrane-bound targets while simultaneously engaging receptors that naturally shuttle material into the lysosome, the cell's built-in recycling and disposal system.

That distinction separates Lycia Therapeutics from many protein degradation companies focused primarily on intracellular targets. Because extracellular proteins have historically remained difficult to target through conventional degradation approaches, the LYTAC platform creates opportunities across disease categories that previously offered limited therapeutic options.

For investors, platform technologies capable of repeatedly generating new therapeutic candidates represent a fundamentally different risk profile than companies built around a single molecule. Sometimes the biggest leap in biotechnology is not inventing a new machine; it is realizing biology has been quietly running one all along.

Market Context

The Lycia Therapeutics financing reflects the changing character of biotechnology investing. The market has become significantly more selective over the past several years, and investors increasingly reward companies demonstrating scientific validation, experienced leadership, repeatable execution, and diversified pipelines rather than early-stage narratives centered on a single clinical program.

Lycia Therapeutics fits that profile. The company has attracted support across multiple financing rounds from institutional healthcare investors while maintaining a strategic relationship with Eli Lilly and Company. Returning investors frequently signal growing confidence built through accumulated scientific evidence and operational execution.

Oversubscribed financings rarely emerge from compelling presentations alone. They are usually the result of years spent generating data, refining platforms, attracting experienced leadership, and reducing technical uncertainty, because biology has little patience for storytelling unsupported by evidence, and sophisticated investors tend to adopt the same attitude.

Competitive Position

Protein degradation has become one of biotechnology's fastest-evolving fields, but not every platform addresses the same biological landscape. Lycia Therapeutics has established its position around extracellular protein degradation through the LYTAC platform, creating opportunities beyond the reach of conventional intracellular degradation technologies.

Its lead pipeline reflects that strategy. LCA-0061 targets immunoglobulin E for allergic diseases, including food allergy, allergic asthma, and chronic spontaneous urticaria, while LCA-0321 focuses on thyroid-stimulating hormone receptor autoantibodies associated with Graves' disease and thyroid eye disease.

The company is also advancing LCA-0391, a development candidate targeting MuSK-positive myasthenia gravis, alongside additional discovery-stage programs across autoimmune and inflammatory diseases. Viewed individually, these programs represent promising therapeutic candidates. Viewed collectively, they demonstrate something potentially more valuable: a scientific platform capable of producing multiple development opportunities across distinct disease categories.

What This Signals for Biotech Investors

The Lycia Therapeutics Series D financing illustrates where experienced healthcare investors continue finding conviction despite a disciplined capital environment. Institutional investors participating in this round are backing more than individual therapeutic candidates. They are supporting a technology platform designed to generate multiple clinical programs over time, an approach that aligns with how many long-term biotechnology investors increasingly evaluate scientific innovation.

Lycia Therapeutics has assembled a financing history that includes multiple oversubscribed equity rounds, a strategic pharmaceutical collaboration with Eli Lilly and Company, experienced scientific leadership, and a growing pipeline approaching key clinical milestones. Those characteristics place the company among a group of biotechnology businesses attempting to build durable innovation engines rather than one-product success stories.

For founders across the broader life sciences ecosystem, there is another takeaway worth remembering. Capital has not disappeared; expectations have changed. The market continues rewarding ambitious science while reserving its strongest support for teams capable of pairing breakthrough platforms with disciplined execution, credible leadership, and measurable progress.